Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer

References

• GiulianoABreast DisordersMcPheeSPapdakisMCurrent Medical Diagnosis and Treatment48th edNew YorkMcGraw-Hill2009630654
   Google Scholar
• RossJSSlodkowskaEASymmansWFPusztaiLRavdinPMHortobagyiGNThe HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicineOncologist200914432036819346299
   PubMed Web of Science ®Google Scholar
• SlamonDJClarkGMWongSGLevinWJUllrichAMcGuireWLHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience198723547851771823798106
   PubMed Web of Science ®Google Scholar
• DawoodSBroglioKBuzdarAUHortobagyiGNGiordanoSHPrognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based reviewJ Clin Oncol2010281929819933921
   PubMed Web of Science ®Google Scholar
• KumarGBadveSMilestones in the discovery of HER2 proto-oncogene and trastuzumab (herceptin)Connections200813914
   Google Scholar
• Herceptin^® (trastuzumab) [prescribing information]South San Francisco, CAGenentech2014
   Google Scholar
• TripathyDSalmonDJCobleighMSafety of treatment of metastatic breast cancer with trastuzumab beyond disease progressionJ Clin Oncol20042261063107015020607
   PubMed Web of Science ®Google Scholar
• VermaSMilesDGianniLEMILIA Study GroupTrastuzumab emtansine for HER2-positive advanced breast cancerN Engl J Med2012367191783179123020162
   PubMed Web of Science ®Google Scholar
• Hoffmann-La RocheA study of trastuzumab emtansine in comparison with treatment of physician’s choice in patients with HER2-positive breast cancer who have received at least two prior regimens of HER2-directed therapy (TH3RESA) Available from: http://clinicaltrials.gov/show/NCT01419197. NLM identifier: NCT01419197Accessed June 18, 2014
   Google Scholar
• YardenYSliwkowskiMXUntangling the ErbB signalling networkNat Rev Mol Cell Biol20012212713711252954
   PubMed Web of Science ®Google Scholar
• YardenYThe EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunitiesEur J Cancer200137Suppl 4S3S811597398
   PubMed Web of Science ®Google Scholar
• HudisCTrastuzumab – mechanism of action and use in clinical practiceN Engl J Med2007357395117611206
   PubMed Web of Science ®Google Scholar
• American Cancer SocietyBreast Cancer Facts and Figures 2011–2012AtlantaAmerican Cancer Society2012 Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-030975.pdfAccessed June 18, 2014
   Google Scholar
• OlsonEMMaximizing human epidermal growth factor receptor 2 inhibition: a new oncologic paradigm in the era of targeted therapyJ Clin Oncol201230141712171422393085
   PubMed Web of Science ®Google Scholar
• HudziakRMLewisGDWingetMFendlyBMShepardHMUllrichAp185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factorMol Cell Biol198993116511722566907
   PubMed Web of Science ®Google Scholar
• CarterPPrestaLGormanCMHumanization of an anti-p185HER2 antibody for human cancer therapyProc Natl Acad Sci U S A19928910428542891350088
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA expands use of Herceptin for early stage breast cancer after primary therapy [press release]Silver Spring, MDUS Food and Drug Administration11162006 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108788.htmAccessed April 20, 2014
   Google Scholar
• OlsonEMNajitaJSSohlJClinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab eraBreast201322452553123352568
   PubMed Web of Science ®Google Scholar
• BaselgaKCortesJKimSBCLEOPATRA Study GroupPertuzumab plus trasuzumab plus docetaxel for metastatic breast cancerN Engl J Med201236610911922149875
   PubMed Web of Science ®Google Scholar
• BlackwellKLBursteinHJStornioloAMRandomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancerJ Clin Oncol20102871124113020124187
   PubMed Web of Science ®Google Scholar
• BlackwellKLBursteinHJStornioloAMOverall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 StudyJ Clin Oncol201230212585259222689807
   PubMed Web of Science ®Google Scholar
• BrossPFBeitzJChenGApproval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemiaClin Cancer Res2001761490149611410481
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationMylotarg (gemtuzumab ozogamicin): market withdrawal [press release]Silver Spring, MDUS Food and Drug Administration6212010 Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm216458.htmAccessed June 9, 2013
   Google Scholar
• GopalAKRamchandrenRO’ConnorOASafety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantationBlood2012120356056822510871
   PubMed Web of Science ®Google Scholar
• ProBAdvaniRBricePBrentuxumab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II studyJ Clin Oncol201230182190219622614995
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA approves new treatment for late-stage breast cancer [Internet]Silver Spring, MDUS Food and Drug Administration2222013 Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm340704.htmAccessed June 10, 2013
   Google Scholar
• GirishSGuptaMWangBClinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancerCancer Chemother Pharmacol20126951229124022271209
   PubMed Web of Science ®Google Scholar
• JunttilaTT1LiGParsonsKPhillipsGLSliwkowskiMXTrastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancerBreast Cancer Res Treat2011128234735620730488
   PubMed Web of Science ®Google Scholar
• IsakoffSJBaselgaJTrastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancerJ Clin Oncol201129435135421172881
   PubMed Web of Science ®Google Scholar
• HigashideEAsaiMOotsuKAnsamitocin, a group of novel maytansinoid antibiotics with antitumour properties from NocardiaNature19772705639721722593392
   PubMed Web of Science ®Google Scholar
• YuTWBaiLCladeDThe biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosumProc Natl Acad Sci U S A200299127968797312060743
   PubMed Web of Science ®Google Scholar
• WangLAmphlettGBlättlerWALambertJMZhangWStructural characterization of the maytansinoid-monoclonal antibody immunoconjugate, hun901-dm1, by mass spectrometryProtein Sci20051492436244616081651
   PubMed Web of Science ®Google Scholar
• Lewis PhillipsGDLiGDuggerDLTargeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugateCancer Res200868229280929019010901
   PubMed Web of Science ®Google Scholar
• EricksonHKLewis PhillipsGDLeipoldDDThe effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugatesMol Cancer Ther20121151133114222408268
   PubMed Web of Science ®Google Scholar
• BarginearMFBudmanDRTrastuzumab-DM1: a review of the novel immuno-conjugate for HER2-overexpressing breast cancerThe Open Breast Cancer Journal2010112530
   Google Scholar
• JunutulaJRFlagellaKMGrahamRAEngineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancerClin Cancer Res201016194769477820805300
   PubMed Web of Science ®Google Scholar
• KropIEBeeramMModiSPhase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancerJ Clin Oncol201028162698270420421541
   PubMed Web of Science ®Google Scholar
• BeeramMKropIEBurrisHAA phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancerCancer2012118235733574022648179
   PubMed Web of Science ®Google Scholar
• BurrisHA3rdRugoHSVukeljaSJPhase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2) –positive breast cancer after prior HER2-directed therapyJ Clin Oncol201129439840521172893
   PubMed Web of Science ®Google Scholar
• KropIELoRussoPMillerKDA phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2 –positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabineJ Clin Oncol201230263234324122649126
   PubMed Web of Science ®Google Scholar
• HurvitzSADirixLKocsisJPhase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancerJ Clin Oncol20133191157116323382472
   PubMed Web of Science ®Google Scholar
• Kadcyla^® (ado-trastuzumab emtansine) [prescribing information]South San Francisco, CAGenentech2013
   Google Scholar
• US Food and Drug AdministrationSafety Alert for Human Medical Products: Kadcyla (ado-trastuzumab emtansine): Drug Safety Communication – Potential Medication Errors Resulting from Name Confusion [press release]Silver Spring, MDUS Food and Drug Administration562013 Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm350817.htmAccessed June 10, 2013
   Google Scholar
• DangCTGianniLRomieuGCardiac safety in a phase II study of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancerJ Clin Oncol201230Suppl 15532
   Web of Science ®Google Scholar
• Hoffmann-La RocheA study of trastuzumab emtansine versus taxane in patients with advanced gastric cancer Available from: http://clinicaltrials.gov/ct2/show/NCT01641939?term=t-dm1+gastric&rank=1. NLM identifier: NCT01641939Accessed June 10, 2013
   Google Scholar
• Hoffmann-La RocheA combination study of trastuzumab emtansine and capecitabine in patients with breast cancer or gastric cancer Available from: http://clinicaltrials.gov/ct2/show/NCT01702558?term=t-dm1+gastric&rank=2. NLM identifier: NCT01702558Accessed June 10, 2013
   Google Scholar
• EllisPABarriosCHImYMARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC)J Clin Oncol201129Suppl 15TPS 102
   Web of Science ®Google Scholar
• Hoffmann-La RocheA study of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE) Available from: http://clinicaltrials.gov/show/NCT01772472. NLM identifier: NCT01772472Accessed June 10, 2013
   Google Scholar
• Dana-Farber Cancer InstituteT-DM1 vs paclitaxel/trastuzumab for Breast (ATEMPT Trial) Available from: http://clinicaltrials.gov/show/NCT01853748. NLM identifier: NCT01853748Accessed April 30, 2014
   Google Scholar
• Hoffmann-La RocheA study of Kadcyla (trastuzumab emtansine) in patients with HER2 positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment Available from: http://clinicaltrials.gov/show/NCT01702571. NLM identifier: NCT01772472Accessed June 10, 2013
   Google Scholar
• Hoffmann-La RocheA study of kadcyla (trastuzumab emtansine) plus perjeta (pertuzumab) following anthracyclines in comparison with herceptin (trastuzumab) plus perjeta and a taxane following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer Available from: http://clinicaltrials.gov/show/NCT01966471. NLM identifier: NCT01966471Accessed April 30, 2014
   Google Scholar
• AbrahamJTrastuzumab emtansine in advanced HER2-positive breast cancerCommunity Oncology20131037173
   Google Scholar
• OlsonEMAbdel-RasoulMMalyJWuCSLinNUShapiroCLIncidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumabAnn Oncol20132461526153323463626
   PubMed Web of Science ®Google Scholar
• OlsonEMLinNUDiPiroPJResponses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancerAnn Oncol2012231939721531783
   PubMed Web of Science ®Google Scholar
• BartschRBerghoffASPreusserMBreast cancer brain metastases responding to primary systemic therapy with T-DM1J Neurooncol2014116120520624065570
   PubMed Web of Science ®Google Scholar
• TessariAPalmieriDDi CosimoSOverview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patientsPharmgenomics Pers Med2013711924403841
   PubMedGoogle Scholar
• BaselgaJVermaSRoJRelationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC)Cancer Res2013738, Supplement 1LB-63
   Web of Science ®Google Scholar
• ClinicalTrials.gov [homepage on the Internet]BethesdaUS National Institutes of Health2014 [updated April 29, 2014]. Available from: http://clinicaltrials.gov/ct2/homeAccessed April 30, 2014
   Google Scholar